-
公开(公告)号:US10356042B1
公开(公告)日:2019-07-16
申请号:US15974723
申请日:2018-05-09
IPC分类号: H04L29/12 , H04M1/2745
摘要: A system, method or computer program product for providing automated contacts books can include an automated contacts book application and a contact details server. The automated contacts book application can run on a computer or mobile computing device and can be configured to interface with the contact details server so that users of the automated contacts book can search for and connect with other users within the contact details server. The automated contacts book can be further configured to permit each user remotely to populate, update and manage availability of their contact details in the automated contacts book applications of all the other users with whom the user is connected within the contact details server. The automated contacts book application can be further configured to interface with the communications systems of the computing devices on which it runs so as to use the up-to-date contact details to send communications.
-
公开(公告)号:US06681861B2
公开(公告)日:2004-01-27
申请号:US10170808
申请日:2002-06-13
IPC分类号: E21B3303
CPC分类号: E21B33/0407 , E21B33/0385
摘要: A system that is usable with a well includes a structure that has a region that is adapted to receive a tubing hanger interface. The system also includes at least one communication connection that penetrates the structure below the region to receive the tubing hanger interface.
摘要翻译: 可用于井的系统包括具有适于接收管道悬挂器接口的区域的结构。 该系统还包括穿过区域下方的结构以接收管道悬挂器接口的至少一个通信连接。
-
公开(公告)号:US5968923A
公开(公告)日:1999-10-19
申请号:US798534
申请日:1997-02-10
申请人: Alexander Roderick MacKenzie , Allan Patrick Marchington , Sandra Dora Meadows , Donald Stuart Middleton
发明人: Alexander Roderick MacKenzie , Allan Patrick Marchington , Sandra Dora Meadows , Donald Stuart Middleton
IPC分类号: C07D205/08 , A61K31/397 , A61K31/40 , A61K31/4427 , A61K31/445 , A61K31/451 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/495 , A61K31/535 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K31/55 , A61K31/553 , A61P1/00 , A61P11/00 , A61P13/00 , A61P13/02 , A61P15/00 , A61P25/00 , A61P25/02 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D205/04 , C07D205/06 , C07D205/085 , C07D211/76 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D451/02 , C07D451/06 , C07D521/00 , A61K401/06 , A61K413/14 , A61K451/02
CPC分类号: C07D231/12 , C07D211/76 , C07D233/56 , C07D249/08 , C07D401/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D451/02
摘要: The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C.sub.3 -C.sub.7 cycloalkyl, aryl or C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl being optionally substituted by fluoro, COOH, --COO(C.sub.1 -C.sub.4 alkyl), C.sub.3 -C.sub.7 cycloalkyl, adamantyl, aryl or het.sup.1, and said C.sub.3 -C.sub.7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, fluoro, fluoro (C.sub.1 -C.sub.4) alkyl and fluoro (C.sub.1 -C.sub.4) Alkoxy; R.sub.1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo and trifluormethyl; R.sup.2 is --CO.sub.2 H, --CONR.sup.3 R.sup.4, --CONR.sup.5 (C.sub.3 -C.sub.7 cycloalkyl), --NR.sup.5 (C.sub.2 -C.sub.5 alkanoyl), --NR.sup.3 R.sup.4, --NR.sup.5 CONR.sup.5 R.sup.6, (C.sub.3 -C.sub.7 cycloalkyl-C.sub.1 -C.sub.4 alkyl)R.sup.5 N--, --NR.sup.5 COCF.sub.3, --NR.sup.5 SO.sub.2 CF.sub.3, --NR.sup.5 (SO.sub.2 C.sub.1 -C.sub.4 alkyl), --NR.sup.5 SO.sub.2 NR.sup.5 R.sup.6, --NR.sup.5 (SO.sub.2 aryl), --N(aryl) (SO.sub.2 C.sub.1 -C.sub.4 alkyl), --OR.sup.5, --O(C.sub.3 -C.sub.7 cycloalkyl), --SO.sub.2 NR.sup.5 R.sup.6, het.sup.3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C.sub.1 -C.sub.4 alkylene; X.sup.1 is a direct link or C.sub.1 -C.sub.6 alkylene; X.sup.2 is a direct link, CO, SO.sub.2, or NR.sup.5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. ##STR1##
摘要翻译: PCT No.PCT / EP95 / 03054 Sec。 371日期1997年2月10日 102(e)日期1997年2月10日PCT提交1995年7月29日PCT公布。 出版物WO96 / 05193 日期:1996年2月22日本发明提供式(I)化合物及其药学上可接受的盐,其中R为C 3 -C 7环烷基,芳基或C 1 -C 6烷基,所述C 1 -C 6烷基,所述C 1 -C 6烷基任选 被氟,COOH,-COO(C1-C4烷基),C3-C7环烷基,金刚烷基,芳基或het1取代,所述C3-C7环烷基任选被1或2个独立地选自C 1 -C 4烷基,C 3 C 1 -C 4烷氧基,羟基,氟,氟(C 1 -C 4)烷基和氟(C 1 -C 4)烷氧基; R1是苯基,萘基,噻吩基,苯并噻吩基或吲哚基,各自任选被1或2个独立地选自C 1 -C 4烷基,C 1 -C 4烷氧基,卤素和三氟甲基的取代基取代; R2是-CO2H,-CONR3R4,-CONR5(C3-C7环烷基),-NR5(C2-C5烷酰基),-NR3R4,-NR5CONR5R6,(C3-C7环烷基-C1-C4烷基)R5N-,-NR5COCF3, NR5SO2CF3,-NR5(SO2 C1-C4烷基),-NR5SO2NR5R6,-NR5(SO2芳基),-N(芳基)(SO2C1-C4烷基),-OR5,-O(C3-C7环烷基),-SO2NR5R6, 或(a),(b),(c),(d),(e),(f),(g)或(h) X是C 1 -C 4亚烷基; X1是直链或C1-C6亚烷基; X2是直接连接,CO,SO2或NR5CO; m为0,1或2; 以及用于制备含有这种衍生物的速激肽类似物的组合物中使用的中间体。
-
公开(公告)号:US5912244A
公开(公告)日:1999-06-15
申请号:US591500
申请日:1996-07-08
IPC分类号: A61K31/35 , A61K31/352 , A61K31/44 , A61K31/443 , A61K31/50 , A61K31/505 , A61P1/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/02 , A61P15/00 , C07D311/70 , C07D403/04 , C07D405/12 , C07D493/04 , C07F7/18 , C07D311/22 , C07D237/14 , C07D239/32 , C07D241/02
CPC分类号: C07D403/04 , C07D311/70 , C07D405/12 , C07F7/1856
摘要: A compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein X is O, S or NH;R and R.sup.1 are each independently selected from H and C.sub.1 -C.sub.4 alkyl or taken together represent C.sub.2 -C.sub.6 alkylene;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl;R.sup.3 is a 6-membered heterocyclic ring containing 2N hetero-atoms, said ring being linked to X by a ring carbon atom, optionally benzo-fused and optionally substituted, including in the benzo-fused portion, by C.sub.1 -C.sub.6 alkyl, hydroxy, --OR.sup.5, halo, --S(O).sub.m R.sup.5, oxo, amino, --NHR.sup.5, --N(R.sup.5).sub.2, cyano, --CO.sub.2 R.sup.5, --CONH.sub.2, --CONHR.sup.5 or --CON(R.sup.5).sub.2, with the proviso that R.sup.3 is not an N--(C.sub.1 -C.sub.6 alkyl)pyridonyl group;R.sup.4 is phenyl substituted by a hydroxy group and optionally further substituted by 1 or 2 substitutents each independently selected from hydroxy, C.sub.1 -C.sub.6 alkyl, --OR.sup.5, halo, cyano and nitro;R.sup.5 is C.sub.1 -C.sub.6 alkyl;R.sup.6 is --OR.sup.5, --NHR.sup.5, --N(R.sup.5).sub.2, --SR.sup.5 or --NHR.sup.9 ;R.sup.7 is cyano;R.sup.8 is --OR.sup.5, --NHR.sup.5, --N(R.sup.5).sub.2, or --NHR.sup.9 ;R.sup.9 is phenyl optionally substituted by C.sub.1 -C.sub.6 alkyl, hydroxy, --OR.sup.5, halo, cyano or nitro; andm is 0, 1 or 2.
摘要翻译: PCT No.PCT / EP94 / 02387第 371日期:1996年7月8日 102(e)日期1996年7月8日PCT 1994年7月18日PCT公布。 公开号WO95 / 04730 日期:1995年2月16日具有下式的化合物或其药学上可接受的盐,其中X为O,S或NH; R和R 1各自独立地选自H和C 1 -C 4烷基或一起代表C 2 -C 6亚烷基; R2是H或C1-C4烷基; R3是含有2N个杂原子的6元杂环,所述环通过环碳原子与X连接,任选苯并稠合并任选被取代,包括苯并稠合部分中的C 1 -C 6烷基,羟基, -OR 5,卤代,-S(O)m R 5,氧代,氨基,-NHR 5,-N(R 5)2,氰基,-CO 2 R 5,-CONH 2,-CONHR 5或-CON(R 5)2, 不是N-(C 1 -C 6烷基)吡啶酮基; R4是被羟基取代的苯基,并任选进一步被1或2个取代基取代,各自独立地选自羟基,C 1 -C 6烷基,-OR 5,卤素,氰基和硝基; R5是C1-C6烷基; R6是-OR5,-NHR5,-N(R5)2,-SR5或-NHR9; R7是氰基; R8是-OR5,-NHR5,-N(R5)2或-NHR9; R9为任选被C 1 -C 6烷基,羟基,-OR 5,卤素,氰基或硝基取代的苯基; m为0,1或2。
-
公开(公告)号:US5846965A
公开(公告)日:1998-12-08
申请号:US788001
申请日:1997-01-24
申请人: Alexander Roderick MacKenzie , Allan Patrick Marchington , Sandra Dora Meadows , Donald Stuart Middleton
发明人: Alexander Roderick MacKenzie , Allan Patrick Marchington , Sandra Dora Meadows , Donald Stuart Middleton
IPC分类号: A61K31/505 , A61K31/506 , A61K31/535 , A61K31/5355 , A61P1/00 , A61P11/00 , A61P13/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , A61P25/28 , A61P29/00 , A61P37/08 , A61P43/00 , C07D403/06 , C07D413/06 , A61K31/395 , C07D205/04 , C07D243/08 , C07D403/14
CPC分类号: C07D403/06 , C07D413/06
摘要: Compounds of the formula: ##STR1## wherein: X is O, NH or NR.sup.1 ; R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4)alkyl, aryl or aryl (C.sub.1 -C.sub.4)alkyl; wherein the C.sub.1 -C.sub.6 alkyl group is optionally substituted by fluorine and the C.sub.3 -C.sub.7 cycloalkyl or C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4 )alkyl group is optionally substituted in the cycloalkyl ring by up to two substituents each independently selected from halo, C.sub.1 -C.sub.4 alkoxy or halo(C.sub.1 -C.sub.4)alkoxy; R.sup.2 is phenyl optionally substituted with one or two halo substituents, indolyl or thienyl; R.sup.3 is NH.sub.2, --NR.sup.4 SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --NR.sup.4 SO.sub.2 aryl, --NR.sup.4 CO(C.sub.1 -C.sub.6 alkyl), --NR.sup.4 CO aryl or a 5 to 7-membered N-linked cyclic group incorporating W in the ring wherein W is O, NR.sup.5, CH(OH), CHCO.sub.2 H, CHN(R.sup.4).sub.2, CHF, CF.sub.2, C.dbd.O or CH.sub.2 ; R.sup.4 is H or C.sub.1 -C.sub.6 alkyl; R.sup.5 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.6)alkyl, C.sub.2 -C.sub.6 alkanoyl, C.sub.4 -C.sub.8 cycloalkanoyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.2 -C.sub.6)alkanoyl, aryl CO--, C.sub.1 -C.sub.6 alkyl SO.sub.2 --, C.sub.3 -C.sub.7 cycloalkyl SO.sub.2 --, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.6)alkyl SO.sub.2 --, aryl-SO.sub.2 -- or (R.sup.6).sub.2 NSO.sub.2 --, wherein each R.sup.6 is independently H or C.sub.1 -C.sub.4 alkyl or the two groups may be joined to form with the nitrogen atom to which they are attached, a pyrrolidinyl, piperidino, morphlino or piperazinyl group; m is 0, 1 or 2 with the proviso that m is not 0 when W is NR.sup.5, C.dbd.O, or O; and n is an integer of from 1 to 4; are neurokinin receptor antagonists of utility in the treatment of a variety of medical conditions including urinary incontinence, asthma and related conditions.
摘要翻译: 下式的化合物:其中:X是O,NH或NR1; R1是C1-C6烷基,C3-C7环烷基,C3-C7环烷基(C1-C4)烷基,芳基或芳基(C1-C4)烷基; 其中C 1 -C 6烷基任选被氟取代,并且C 3 -C 7环烷基或C 3 -C 7环烷基(C 1 -C 4)烷基任选在环烷基环中被至多两个各自独立地选自卤素, C4烷氧基或卤代(C1-C4)烷氧基; R2是任选被一个或两个卤素取代基取代的苯基,吲哚基或噻吩基; R 3是NH 2,-NR 4 SO 2(C 1 -C 6烷基),-NR 4 SO 2芳基,-NR 4 CO(C 1 -C 6烷基),-NR 4 CO芳基或在其中W为W的5至7元N-连接的环状基团 O,NR 5,CH(OH),CHCO 2 H,CHN(R 4)2,CHF,CF 2,C = O或CH 2; R4是H或C1-C6烷基; R5是H,C1-C6烷基,C3-C7环烷基,C3-C7环烷基(C1-C6)烷基,C2-C6烷酰基,C4-C8环烷酰基,C3-C7环烷基(C2-C6)烷酰基,芳基CO-, C 1 -C 6烷基SO 2 - ,C 3 -C 7环烷基SO 2 - ,C 3 -C 7环烷基(C 1 -C 6)烷基SO 2 - ,芳基-SO 2 - 或(R 6)2 NSO 2 - ,其中每个R 6独立地是H或C 1 -C 4烷基或 两个基团可以与它们所连接的氮原子结合形成吡咯烷基,哌啶子基,吗啉基或哌嗪基; m为0,1或2,条件是当W为NR5,C = O或O时,m不为0; n为1〜4的整数, 是用于治疗各种医学状况(包括尿失禁,哮喘和相关病症)的神经激肽受体拮抗剂。
-
公开(公告)号:US5741790A
公开(公告)日:1998-04-21
申请号:US789698
申请日:1997-01-27
申请人: Alexander Roderick Mackenzie , Allan Patrick Marchington , Donald Stuart Middleton , Sandra Dora Meadows
发明人: Alexander Roderick Mackenzie , Allan Patrick Marchington , Donald Stuart Middleton , Sandra Dora Meadows
IPC分类号: A61K31/00 , A61K31/495 , A61K31/4965 , A61K31/497 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61P1/00 , A61P3/08 , A61P11/00 , A61P13/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/20 , A61P25/24 , A61P25/26 , A61P25/28 , A61P29/00 , A61P37/08 , A61P43/00 , C07D211/88 , C07D401/06 , C07D451/02 , C07D401/14 , C07D413/14
CPC分类号: C07D401/06 , C07D211/88
摘要: The present invention provides compounds of the formula (I): ##STR1## and the pharmaceutically acceptable salts thereof, wherein R is C.sub.3 -C.sub.7 cycloalkyl, aryl or C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl being optionally substituted by fluoro, --COOH, --COO(C.sub.1 -C.sub.4) alkyl, C.sub.3 -C.sub.7 cycloalkyl, adamantyl, aryl or het.sup.1, and said C.sub.3 -C.sub.7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, fluoro, fluoro(C.sub.1 -C.sub.4) alkyl and fluoro(C.sub.1 -C.sub.4)alkoxy; R.sup.1 is phenyl, benzyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo and trifluoromethyl; R.sup.2 represents various groups; X is C.sub.1 -C.sub.4 alkylene; and X.sup.1 is a direct link or C.sub.1 -C.sub.6 alkylene. Such compounds and salts are useful as tachykinin antagonists.
摘要翻译: 本发明提供式(I)化合物:其中R 1为C 3 -C 7环烷基,芳基或C 1 -C 6烷基,所述C 1 -C 6烷基任选被氟取代 ,-COOH,-COO(C1-C4)烷基,C3-C7环烷基,金刚烷基,芳基或het1,并且所述C3-C7环烷基任选被1或2个独立地选自C 1 -C 4烷基,C 3 -C 7 环烷基,C 1 -C 4烷氧基,羟基,氟,氟(C 1 -C 4)烷基和氟(C 1 -C 4)烷氧基; R1是苯基,苄基,萘基,噻吩基,苯并噻吩基或吲哚基,各自任选被1或2个独立地选自C 1 -C 4烷基,C 1 -C 4烷氧基,卤素和三氟甲基的取代基取代; R2代表各种基团; X是C 1 -C 4亚烷基; X1是直链或C1-C6亚烷基。 这些化合物和盐可用作速激肽拮抗剂。
-
公开(公告)号:US08902077B2
公开(公告)日:2014-12-02
申请号:US11425939
申请日:2006-06-22
IPC分类号: G01V3/00
CPC分类号: E21B33/0355 , E21B43/01 , E21B47/12 , H01M8/04007 , H01M8/04156 , H01M8/24 , H01M8/241 , H01M8/2425 , H04B11/00 , H04B13/02
摘要: A subsea communication system is used to communicate between a position that is proximal to a surface of the sea and an apparatus of the seabed. The subsea communication system includes an umbilicalless communication system.
摘要翻译: 海底通信系统用于在靠近海洋表面的位置和海床的设备之间进行通信。 海底通信系统包括无脐通信系统。
-
公开(公告)号:US07261162B2
公开(公告)日:2007-08-28
申请号:US10641652
申请日:2003-08-15
CPC分类号: H01Q1/04 , E21B41/0007 , E21B47/12 , H04B3/50 , H04B10/25
摘要: A subsea communications module includes an interface to communicate with a surface facility over a communications link using a packet-based protocol. The communications link can be implemented with a fiber optic line, wire-based line, and/or other types of communications lines.
摘要翻译: 海底通信模块包括使用基于分组的协议通过通信链路与地面设施通信的接口。 通信链路可以用光纤线,基于线的线路和/或其他类型的通信线路来实现。
-
公开(公告)号:US07123162B2
公开(公告)日:2006-10-17
申请号:US10127522
申请日:2002-04-22
申请人: Roderick Mackenzie , John A. Kerr , Alan Johnston
发明人: Roderick Mackenzie , John A. Kerr , Alan Johnston
IPC分类号: G01V8/24
CPC分类号: E21B33/0355 , E21B43/01 , E21B47/12 , H01M8/04007 , H01M8/04156 , H01M8/24 , H01M8/241 , H01M8/2425 , H04B11/00 , H04B13/02
摘要: A subsea communication system is used to communicate between a position that is proximal to a surface of the sea and an apparatus of the seabed. The subsea communication system includes an umbilicalless communication system.
-
公开(公告)号:US6022971A
公开(公告)日:2000-02-08
申请号:US13152
申请日:1998-01-26
申请人: Alexander Roderick MacKenzie , Allan Patrick Marchington , Donald Stuart Middleton , Sandra Dora Meadows
发明人: Alexander Roderick MacKenzie , Allan Patrick Marchington , Donald Stuart Middleton , Sandra Dora Meadows
IPC分类号: A61K31/00 , A61K31/495 , A61K31/4965 , A61K31/497 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61P1/00 , A61P3/08 , A61P11/00 , A61P13/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/20 , A61P25/24 , A61P25/26 , A61P25/28 , A61P29/00 , A61P37/08 , A61P43/00 , C07D211/88 , C07D401/06 , C07D451/02 , C07D205/02 , C07D401/02 , C07D401/14
CPC分类号: C07D401/06 , C07D211/88
摘要: The present invention provides compounds of the formula (I): ##STR1## and the pharmaceutically acceptable salts thereof, wherein R is C.sub.3 -C.sub.7 cycloalkyl, aryl or C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl being optionally substituted by fluoro, --COOH, --COO(C.sub.1 -C.sub.4) alkyl, C.sub.3 -C.sub.7 cycloalkyl, adamantyl, aryl or het.sup.1, and said C.sub.3 -C.sub.7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, fluoro, fluoro(C.sub.1 -C.sub.4) alkyl and fluoro(C.sub.1 -C.sub.4)alkoxy;R.sup.1 is phenyl, benzyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo and trifluoromethyl;R.sup.2 represents various groups;X is C.sub.1 -C.sub.4 alkylene; andX.sup.1 is a direct link or C.sub.1 -C.sub.6 alkylene.Such compounds and salts are useful as tachykinin antagonists.
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐,其中R为C 3 -C 7环烷基,芳基或C 1 -C 6烷基,所述C 1 -C 6烷基任选被氟取代,-COOH,-COO (C 1 -C 4)烷基,C 3 -C 7环烷基,金刚烷基,芳基或het1,并且所述C 3 -C 7环烷基任选被1或2个独立地选自C 1 -C 4烷基,C 3 -C 7环烷基,C 1 -C 4烷氧基 ,羟基,氟,氟(C 1 -C 4)烷基和氟(C 1 -C 4)烷氧基; R1是苯基,苄基,萘基,噻吩基,苯并噻吩基或吲哚基,各自任选被1或2个独立地选自C 1 -C 4烷基,C 1 -C 4烷氧基,卤素和三氟甲基的取代基取代; R2代表各种基团; X是C 1 -C 4亚烷基; X1是直链或C1-C6亚烷基。 这些化合物和盐可用作速激肽拮抗剂。
-
-
-
-
-
-
-
-
-